This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
by Zacks Equity Research
Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.
Novartis Beats on Q3 Earnings and Sales, Raises 2024 Outlook
by Zacks Equity Research
NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its outlook for 2024.
Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Novartis (NVS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
The Zacks Analyst Blog Novartis, Reddit and Check Point Software Technologies
by Zacks Equity Research
Novartis, Reddit and Check Point Software Technologies are included in this Analyst Blog.
Buy 3 Stocks Likely to Gain on Potential Q3 Earnings Beat
by Nalak Das
We have narrowed our search to three large-cap stocks set to report earnings results tomorrow. These are: NVS, RDDT, CHKP.
NVS vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Novartis (NVS) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen
by Zacks Equity Research
Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen are included in this Analyst Blog.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen
by Zacks Equity Research
Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen are included in this Analyst Blog.
Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know
by Zacks Equity Research
INCY's third-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
by Ahan Chakraborty
Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.
Novartis Gets CHMP Recommendation for Kisqali in Broader Population
by Zacks Equity Research
The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU
by Zacks Equity Research
ALNY stock gains after submitting a regulatory application in the EU, seeking the approval of vutrisiran to treat ATTR amyloidosis with cardiomyopathy.
Bayer Seeks Approval for Elinzanetant for Vasomotor Symptoms in EU
by Zacks Equity Research
BAYRY submits an application seeking EMA approval of elinzanetant for treating hot flashes associated with menopause or adjuvant endocrine therapy.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Novartis (NVS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Roche Wins FDA Nod for Breast Cancer Drug in First-Line Setting
by Zacks Equity Research
RHHBY obtains FDA approval for Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Here's Why Novartis (NVS) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
NVS or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
5 Low-Leverage Stocks to Buy Buoyed by Impressive Tech Earnings
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You can buy SAFRY, NVS, KEX, ACGL and LMB.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
by Zacks Equity Research
Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
by Zacks Equity Research
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.